tapebrief

NDSN · Q2 2026 Earnings

Bullish

Nordson Corporation

Reported May 20, 2026

30-second summary

Nordson delivered 8.5% revenue growth to $741M, 7% organic, with all three segments and all three regions positive — and raised full-year sales and EPS guidance on the back of an 18% YoY backlog build. Management's language was atypically confident for a precision technology supplier: they framed midpoint as their base case and said only a "meaningful slowdown" gets them to the low end. The electronics/semi inflection in ATS (10.1% growth) and a medical recovery (back to 8% from a soft Q1) are doing the work.

Headline numbers

EPS

Q2 FY2026

$2.86

Revenue

Q2 FY2026

$0.74B

+8.5% YoY

Gross margin

Q2 FY2026

54.5%

Operating margin

Q2 FY2026

26.6%

Key financials

Q2 FY2026
MetricQ2 FY2026YoY
Revenue$0.74B+8.5%
EPS$2.86
Gross margin54.5%
Operating margin26.6%

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2026
SegmentQ2 FY2026YoY
Industrial Precision Solutions$0.35B+9.9%
Medical and Fluid Solutions$0.213B+5.0%
Advanced Technology Solutions$0.178B+10.1%

Other KPIs

Q2 FY2026
SegmentQ2 FY2026YoY
Americas$0.308B+5.4%
Europe$0.194B+12.7%
Asia Pacific$0.238B+9.2%
EBITDA$235.2 million
EBITDA Margin31.7%
Backlog Growth YoY+18%
Organic Sales Growth6.6%
IPS EBITDA Margin35.3%
Medical and Fluid Solutions EBITDA Margin37.1%
Advanced Technology Solutions EBITDA Margin27.2%
Free Cash Flow Conversion119%

Management tone

Management spoke with notably more conviction than the typical precision-tools script. Rather than the usual "we're watching macro carefully" hedge, they inverted the framing — midpoint is the base case, downside requires a macro shock. "We have a high level of confidence in the midpoint of our range, and it would take a meaningful slowdown in order activity driven by macro conditions to move us towards the low end." That's a guidance-raise call structured to push consensus toward the upper half.

Medical shifted from a Q1 concern into a recovery story. Management characterized the segment as "steadily returning to normalized growth" with long-term drivers (aging population, minimally invasive procedures, biopharma diagnostics) reiterated as intact. The 8% segment growth print in Q2 (Somerville Q&A) versus a "modest" Q1 frames this quarter as the pivot.

The portfolio-mix narrative is being repositioned as structural rather than cyclical. "More than 50% of our portfolio is now in growth end markets, including semiconductor, electronics, and medical, with remaining exposures in more stable GDP plus end markets." This is management asking investors to re-rate the cyclicality of the business — moving away from the industrial-discretionary bucket.

Incremental margin expectations were actively reset downward. Management was explicit in Q&A that ~50% incremental conversion isn't realistic this year given inflation and tariffs, and that the focus is maintaining margin rather than expanding it. The honesty here — pre-empting the "why aren't incrementals at historical levels" question — was deliberate expectation management against a raised top-line.

FX flipped from H1 tailwind to H2 neutral, which management called out unprompted. "At current exchange rates, foreign exchange, which has been a contributor to the growth in the first half, will be essentially neutral in the second half year over year." This matters because the FY raise is therefore organic-driven, not currency-driven — a higher-quality raise than the surface print suggests.

Recurring themes management leaned on this quarter:

Record sales and earnings across all segmentsOrganic growth acceleration with 7% in Q2 and backlog up 18% YoYElectronics and semiconductor demand inflection driving ATS segmentMedical recovery after soft Q1Strategic M&A deployment in precision agricultureStrong free cash flow conversion and capital allocation discipline

Risks management surfaced:

Potential for a range of macroeconomic outcomes requiring prudenceMeaningful slowdown in order activity driven by macro conditionsMedical product startup headwinds in select interventional linesGeneral automotive electronics remaining mutedFX volatility (though noted as neutral for H2)

Q&A highlights

Matt Somerville · DA Davidson

Can management confirm medical segment growth is sustainably on track for 6-8% normalized growth rates? What details can be provided on the interventional product headwind and material change impact?

Medical achieved 8% growth in Q2 and is tracking toward normalized 6-8% growth rates. The interventional product headwind is a near-term regulatory-required material change causing operational inefficiencies, with clear line of sight to resolution. Strong order entry and backlog build in medical supports confidence in normalized growth return.

Medical segment 8% growth in Q2Target normalized growth rate: 6-8%Regulatory-required material change is a one-time changeover issueStrong medical business order entry and backlog buildup

Walter Liptak · Seaport Research

Can management quantify ATS order strength (single vs double digit growth)? Why is the transition from electronics dispense to test & inspection showing apparent lag?

Backlog up 18% with particular strength in ATS segment, implying double-digit order growth at least in line with or better than 18% overall. No actual lag between dispense and T&I; dispense has more units per line than T&I historically. Both businesses seeing similar demand levels; current strength in dispense is mix-driven, not market-driven.

Overall backlog up 18%ATS backlog growth contributing disproportionately to 18%ATS orders growing at double-digit rates (at or better than 18%)Dispense and T&I demand at similar levels; mix reflects more dispense units per application

Jeff Hammond · KeyBank Capital Markets, Inc.

What is driving the splat-down margins in industrial despite decent growth? What about price-cost and mix dynamics? How will margins trend in H2?

IPS delivered 4% organic growth with best-in-class margins for the company. Inflationary environment (including tariffs) impacting all businesses. Managing through selective pricing and cost offsets. Short-term issue; focus is maintaining margin performance while maximizing growth, not expanding margins in inflationary environment. Incrementals in 50% range not realistic this year.

IPS 4% organic growth in H1Inflationary environment including tariffs impacting input costs (components, resins)Last year incrementals were ~50% range; this year focused on maintaining margins while growingPackaging/adhesive dispensing above market growth; plastics/coatings improving; precision ag growing nicely

Mike Halloran · Baird

Is guidance assuming sequential normalcy Q3-Q4, or is there flattening expected? What are backlog conversion timelines and any signs of capacity-driven backlog buildout, especially in ETS?

No fundamental change in backlog conversion; majority turns within six months, some within quarter, minority bleeding into 2027. Good visibility to Q3 with 60% consumables/single-use business. Prudent on Q4 due to macro dynamics (potential raw material shortages, broader pullback risk), but no pullback seen yet in demand patterns. Not taking in one-year-out orders.

Backlog majority converts within 6 monthsSome backlog extending into 2027 (minority portion)60% of business is consumables/single-use turnoverHigh confidence in Q3 visibility; prudent on Q4 due to macro risks

What to watch into next quarter

Whether ATS revenue growth sustains at or above 10% — management implicitly tied FY upper-end delivery to electronics/semi momentum continuing

Whether the medical interventional startup headwind reverses to a tailwind in Q3-Q4, or if margin compression persists past Q2

Q3 organic growth print versus the ~6-7% Q2 run-rate, and whether backlog conversion delivers the $760-790M revenue band

IPS incremental margin trajectory — management has guided away from 50%+ but the actual incremental needs to clear the Q1 baseline (Q2 was already +300bps improvement vs Q1)

Order entry momentum in Q4 — Halloran's question on whether prudence on Q4 reflects actual softening or just conservatism; first signs of any customer order pull-back

Sources

  1. NDSN Q2 FY2026 press release (8-K Ex. 99.1), filed 2026-05-20
  2. NDSN Q2 FY2026 earnings call transcript

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.